Antibody & AOC Candidate Assessment & CMC Strategy

The successful development of antibody and antibody-oligonucleotide conjugate (AOC) therapeutics requires early identification of molecular characteristics, development risks, and regulatory considerations. Protheragen provides integrated candidate assessment and CMC strategy services to support informed decision-making and establish efficient development pathways from early discovery to clinical advancement. By combining developability evaluation, protein characterization, and CMC planning expertise, Protheragen helps clients assess candidate suitability, define critical quality attributes (CQAs), optimize development strategies, and prepare for IND/BLA submissions.

Overview of Antibody & AOC Candidate Assessment & CMC Strategy

Candidate assessment and CMC (Chemistry, Manufacturing, and Controls) strategy development are critical early-stage activities in the development of antibody and antibody-oligonucleotide conjugate (AOC) therapeutics. These processes focus on evaluating candidate molecules, understanding their key quality attributes, identifying potential development risks, and establishing a comprehensive pathway for subsequent process development and regulatory submission.

Candidate assessment involves the systematic evaluation of molecular characteristics, structural stability, biological properties, and manufacturability of therapeutic candidates. For antibody molecules, key considerations include expression potential, aggregation tendency, molecular integrity, and functional activity. For AOC therapeutics, additional factors such as conjugation characteristics, antibody-payload compatibility, molecular stability, and product heterogeneity require careful evaluation.

CMC strategy integrates scientific understanding of the candidate molecule with manufacturing and regulatory requirements. It defines development approaches for critical quality attributes (CQAs), analytical characterization, process development, formulation optimization, stability studies, and GMP manufacturing readiness.

Fig.1 Considerations of developability-related measurements at the different stages from target evaluation to IND filing. (Zhang W, et al., 2022)

Our Services

Protheragen offers integrated early-stage development solutions designed to support antibody and AOC programs throughout the transition from discovery candidates to clinical development.

Key Capabilities

Protheragen combines multidisciplinary expertise in biologics development, analytical characterization, and CMC strategy to support comprehensive candidate assessment and development planning.

Our capabilities include:

Through integrated scientific evaluation and CMC-focused planning, Protheragen helps clients establish reliable development strategies for next-generation antibody and AOC therapeutics.

Critical Quality Attribute (CQA) Assessment

Critical quality attributes (CQAs) are measurable physical, chemical, biological, or microbiological characteristics that are essential for ensuring the quality, safety, and efficacy of therapeutic products. Identification and evaluation of CQAs are fundamental components of antibody and antibody-oligonucleotide conjugate (AOC) development, providing a scientific basis for process development, analytical strategy, and regulatory submission.

For antibody therapeutics, CQA assessment focuses on key product attributes such as molecular identity, purity, structural integrity, stability, glycosylation profile, and biological activity. For AOC molecules, additional quality considerations are required, including conjugation characteristics, drug-to-antibody ratio (DAR), payload distribution, and conjugate stability.

Protheragen integrates analytical characterization data, product understanding, and CMC development expertise to support CQA identification and evaluation. This approach helps establish appropriate quality targets, define control strategies, and ensure alignment between product characteristics, manufacturing processes, and regulatory expectations.

Why Choose Protheragen

• Integrated Early-Stage Development Platform

Protheragen provides a comprehensive approach combining candidate evaluation, analytical characterization, and CMC strategy development to support informed decision-making at the earliest stages of development.

• Expertise in Complex Antibody-Based Therapeutics

Our experience in antibody and AOC development enables tailored assessment strategies addressing the unique challenges of complex biologics, including molecular stability, conjugation characteristics, and manufacturing feasibility.

• Risk-Based CMC Strategy Development

By integrating analytical data with process and regulatory considerations, Protheragen helps identify potential risks early and establish efficient development pathways.

• Seamless Transition to Process Development and Manufacturing

Candidate assessment results are directly connected with downstream activities, including cell line development, process optimization, analytical method development, and GMP manufacturing.

A well-designed candidate assessment and CMC strategy provides the foundation for successful antibody and AOC development. Protheragen supports clients with integrated evaluation and planning services to reduce development uncertainty, optimize candidate selection, and accelerate progression toward IND submission and clinical manufacturing. Contact us to develop a customized assessment and CMC strategy for your antibody and AOC programs.